|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Two 24-nor-triterpenoid carboxylic acids from Acanthopanax trifoliatus显示文摘 | LISCHEWSKI M TY P D KUTSCHABSKY L | 1985 | Phytochemistry1985，24，10： | 1 |
| 2 | 3α,11c-Dihydroxy-23-oxolup-20(29)-en-28-oic acid from Aeanthopanax trifoliatus显示文摘 | TY P D LISCHEWSKI M PHIET H V | 1985 | Phytochemistry1985，24，4： | 1 |
| 3 | Retinal microvascular abnormalities and renal dys- function: the Atherosclerosis Risk in Communities Study 显示文摘 | Wong TY Coresh J Klein R Muntner P Couper D J Sharrett AR | 2004 | J Am Soc Nephro12004，15，9： | 1 |
| 4 | ChxR is a transcrip- tional activator in Chlamydia显示文摘 | Koo 1 C Wahhers D Het]ty P S | 2006 | Proe Nail Acad Sci USA2006，103，3： | 1 |
| 5 | False smut: a threat to rice growers in Assam 显示文摘 | Baruah B P Senapo ty D A liM S | 1992 | Indian Journal of Mycology and Plant Pathology1992，22，3： | 1 |
| 6 | 3or, 11 a-dihydroxy-lup- 20(29 )-ene-23, 28-dioic acid from Schefflera octophylla 显示文摘 | Lischewski M Ty P D Schmidt J | 1984 | Phytochemistry1984，23，8： | 1 |
| 7 | Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding 显示文摘 | Scheid JF Mouquet H Ueberheide B Diskin R Klein F Oliveira TY Pietzsch J Fenyo D Abadir A Velinzon K Hurley A Myung S Boulad F Poignard P Burton DR Pereyra F Ho DD Walker BD Seaman MS Bjorkman PJ Chait BT Nussenzweig MC | 2011 | Science2011，333，6049： | 1 |
| 8 | Stress,coping andm en ta lw el lbeing in hospital nu rses显示文摘 | Ty ler P C ushw ay D | 1992 | StressM ed icine1992，，8： | 1 |
| 9 | PEG 400, a hydrophilic molecular probe for measuring intestinal permeability显示文摘 | Ma TY Hollander D Krugliak P | 1990 | Gastroenterology1990，98，1： | 1 |
| 10 | Structural basis of the Ca(2+)-dependent association between S100C (S100A11) and its target,the N-terminal part of annexin I显示文摘 | Réty S Osterloh D Arié J P | 2000 | Structure2000，8，2： | 1 |
| 11 | Cardiovasctflar risk factors for retinal vein occlusion and arteriolar emboli: The atherosclerosis risk in communities & car- diovascular health studies 显示文摘 | Wong TY Larsen EK Klein R Mitchell P Couper D J Klein BE | 2005 | Ophthalmology2005，112，4： | 1 |
| 12 | Mutations involved in Aicardi-Goutieres syndrome implicate SAMHD1 as regulator of the innate immune response 显示文摘 | Rice GI Bond J Asipu A Brunette RL Manfield IW Carr IM Fuller JC Jackson RM Lamb T Briggs TA Ali M GomaU H Couthard LR Aeby A Attard-Montalto SP Bertini E Bodemer C Brockmann K Bmeton LA Corry PC Desguerre I Fazzi E Cazorla AG Gener B Hamel BCJ Heiberg A Hunter M van der Knaap MS Kumar R Lagae L Landrieu PG Lourenco CM Marom D McDermott MF van der Merwe W Orcesi S PrendiviUe JS Rasmussen M Shalev SA Soler DM Shinawi M Spiegel R Tan TY Vanderver A Wakeling EL Wassmer E Whittaker E Lebon P Stetson DB Bonthron DT Crow YJ 2009 | 2009 | Nat Genet2009，41，7： | 1 |
| 13 | Cornell net carbohydrate and protein system model:an model for precision feeding of dairy cattle显示文摘 | Ty|utki T P Fox D G Durbala V M et a/ | 2008 | Animal Feed Science and Technology2008，143，17： | 1 |
| 14 | Real-world performance analysis of a novel computational method in the precision oncology of pediatric tumors显示文摘Background The utility of routine extensive molecular profiling of pediatric tumors is a matter of debate due to the high number of genetic alterations of unknown significance or low evidence and the lack of standardized and personalized decision support methods.Digital drug assignment(DDA)is a novel computational method to prioritize treatment options by aggregating numerous evidence-based associations between multiple drivers,targets,and targeted agents.DDA has been validated to improve personalized treatment decisions based on the outcome data of adult patients treated in the SHIVA01 clinical trial.The aim of this study was to evaluate the utility of DDA in pediatric oncology.Methods Between 2017 and 2020,103 high-risk pediatric cancer patients(<21 years)were involved in our precision oncology program,and samples from 100 patients were eligible for further analysis.Tissue or blood samples were analyzed by whole-exome(WES)or targeted panel sequencing and other molecular diagnostic modalities and processed by a software system using the DDA algorithm for therapeutic decision support.Finally,a molecular tumor board(MTB)evaluated the results to provide therapy recommendations.Results Of the 100 cases with comprehensive molecular diagnostic data,88 yielded WES and 12 panel sequencing results.DDA identified matching off-label targeted treatment options(actionability)in 72/100 cases(72%),while 57/100(57%)showed potential drug resistance.Actionability reached 88%(29/33)by 2020 due to the continuous updates of the evidence database.MTB approved the clinical use of a DDA-top-listed treatment in 56 of 72 actionable cases(78%).The approved therapies had significantly higher aggregated evidence levels(AELs)than dismissed therapies.Filtering of WES results for targeted panels missed important mutations affecting therapy selection.Conclusions DDA is a promising approach to overcome challenges associated with the interpretation of extensive molecular profiling in the routine care of high-risk pediatric cancers.Knowledgebase updates enable automatic interpretation of a continuously expanding gene set,a“virtual”panel,filtered out from genome-wide analysis to always maximize the performance of precision treatment planning. | Barbara Vodicska Júlia Déri Dóra Tihanyi Edit Várkondi EnikőKispéter Róbert Dóczi Dóra Lakatos Anna Dirner Mátyás Vidermann Péter Filotás Réka Szalkai-Dénes István Szegedi Katalin Bartyik Krisztina Míta Gábor Réka Simon Péter Hauser György Péter Csongor Kiss Miklós Garami István Peták | 2023 | World Journal of Pediatrics2023，19，10： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员